Segall Bryant & Hamill LLC Has $18.86 Million Stock Holdings in Galapagos NV (NASDAQ:GLPG)

Segall Bryant & Hamill LLC decreased its holdings in shares of Galapagos NV (NASDAQ:GLPG) by 2.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 685,867 shares of the biotechnology company’s stock after selling 19,781 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 1.04% of Galapagos worth $18,861,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. R Squared Ltd bought a new position in shares of Galapagos in the 4th quarter valued at approximately $26,000. GAMMA Investing LLC raised its position in shares of Galapagos by 77.4% in the fourth quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 974 shares during the period. QRG Capital Management Inc. lifted its stake in shares of Galapagos by 21.7% in the fourth quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company’s stock worth $288,000 after buying an additional 1,866 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Galapagos in the third quarter worth $410,000. Finally, American Century Companies Inc. boosted its holdings in shares of Galapagos by 5.9% during the 4th quarter. American Century Companies Inc. now owns 25,852 shares of the biotechnology company’s stock worth $711,000 after buying an additional 1,431 shares during the period. Institutional investors own 32.46% of the company’s stock.

Galapagos Price Performance

Shares of NASDAQ:GLPG opened at $25.53 on Wednesday. Galapagos NV has a 1-year low of $22.36 and a 1-year high of $33.00. The business’s 50 day moving average is $24.97 and its 200-day moving average is $26.98.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. TD Cowen downgraded Galapagos from a “strong-buy” rating to a “strong sell” rating in a research report on Thursday, January 9th. Barclays reaffirmed an “underweight” rating on shares of Galapagos in a report on Thursday, January 23rd. Finally, Morgan Stanley downgraded Galapagos from an “equal weight” rating to an “underweight” rating and dropped their price target for the stock from $31.00 to $22.00 in a research report on Friday, February 14th. Five analysts have rated the stock with a sell rating and four have issued a hold rating to the stock. According to data from MarketBeat.com, Galapagos has an average rating of “Reduce” and a consensus price target of $26.75.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.